Gedeon Richter Launches Extended-Release Version of Armadin Medication
Hungarian pharmaceutical company Gedeon Richter Plc. has introduced Armadin® long, an extended-release formulation containing ethylmethylhydroxypyridine succinate. The drug is indicated for cerebrovascular disorders and other neurological conditions.
Gedeon Richter Plc., a Hungarian pharmaceutical company, has launched Armadin® long, an extended-release formulation of its existing Armadin medication. The active substance in the new preparation is ethylmethylhydroxypyridine succinate.
The drug is intended for adults experiencing consequences of acute cerebrovascular disorders, including stroke and transient ischemic attacks (TIA). It may also be used for mild traumatic brain injuries, various forms of brain dysfunction (encephalopathies), autonomic nervous system dysregulation, and mild cognitive impairments.
Armadin® long belongs to the category of "other drugs acting on the nervous system." Its active ingredient, ethylmethylhydroxypyridine succinate, acts as an antioxidant, protecting cell membranes from potentially harmful free radicals. The medication also exhibits anticonvulsant, calming, and stress-resistance enhancing properties, potentially aiding in slowing the progression of atherosclerosis.
The drug is contraindicated for individuals with acute liver or kidney dysfunction, pregnant or breastfeeding women, and those under 18 years of age, as safety and efficacy have not been established in these groups. Gedeon Richter is a global pharmaceutical company headquartered in Hungary.